TAVI has become a key alternative to surgical aortic valve replacement, supported by strong evidence from randomized trials across all surgical risk levels. The balloon-expandable SAPIEN and self-expanding CoreValve/Evolut valves are established standards, with emerging valve technologies now undergoing direct comparisons against them. Here is a summary of such head-to-head comparisons.
https://t.co/T7nLi02dOJ
Great to get one of the first Evolute FX+ cases done in the U.K. this morning. Complex anatomy with low left coronary artery. Important iteration of proven valve technology to allow optimal coronary access
The beauty of a flexible deliverable valve - here Evolut FX in action over a Lunderquist to overcome two 90 degrees bends with calcium in first one #cardiotwitter @TAVRBot
#ACC2024 LBT SMART trial
➡️Self- vs balloon-expandable TAVR in small annuli
🌎716 all-comer AS pts, 13 countries, 87% women !!
🎯SEV (78% EvolutPRO+)non-inferior 1y clinical outcome, superior valve performance (lower dysfunction/gradient/PPM, higher EOA/DVI)
@NEJM great for 👩
#SMART Trial #ACC24 the largest trial comparing the hemodynamic performance and clinical outcomes of SEV to BEV with more than 85% female representation
🫀SEV was superior to BEV for bioprosthetic valve dysfunction at 12 months for all definitions tested @CardioNerds#TAVR
Wow!
Self-expanding valves in #ACC24 SMART trial with blockbuster results. Powered for superiority!
Can't wait to hear more from structural expert colleagues @JACCJournals
Transcatheter pulmonary valve replacement with self-expanding valves was associated with excellent procedural success rates and excellent short-term hemodynamics.
Read the journal scan for more: https://t.co/9H9nwYh60C #JACC